Novo-Nordisk

What does the company do?

Novo-Nordisk is a Danish pharmaceutical company with a strong record of Research & Development and customer service. Having had a long-term market leadership position in diabetes care, it has recently developed highly effective anti-obesity treatments. These have seen rapid growth in the past few years, with widespread adoption in developed markets. The Investment Manager expects the company to deliver continued strong growth, supported by increased access and duration of use. The Investment Manager also sees the potential for expansion of the addressable market as clinical trials prove the benefit of these products in other indications. While Novo-Nordisk does not have a high dividend yield, it does have a track record of continued dividend growth.